Want to see PHAT full AI Analyst Report?
PHAT Stock Chart & Stats
$13.19
-$0.22(-3.06%)
At close: 4:00 PM EST
$13.19
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$7.61 - $18.31
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.02M
Market Cap
$849.40M
Enterprise Value$1.28K
Total Cash (Recent Filing)$180.90M
Total Debt (Recent Filing)$166.30M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Jul 30, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding79,755,950
10 Day Avg. Volume1,276,163
30 Day Avg. Volume1,017,509
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.25Price Target Upside83.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$334.00M
Bulls Say, Bears Say
Bulls Say
Prescription MomentumSustained, large prescription volumes and rapid year-over-year covered script growth indicate durable commercial adoption and expanding patient base. Strong NBRx conversion among gastroenterologists suggests entrenched prescribing patterns that can support multi-quarter revenue stability and scale.
High Gross MarginAn ~80% gross margin implies favorable product economics and high incremental profitability per unit sold. This structural margin cushion helps absorb commercial and R&D spend, improving the ability to reach operating profitability as revenue scales and protecting cash flow against moderate pricing or cost pressures.
Expense DisciplineMaterial year-over-year reduction in cash OpEx demonstrates durable cost control and alignment of spend with commercial rollout. Lower fixed cash burn improves runway, reduces funding risk, and makes the company’s guidance to reach operating profitability ex‑SBC more credible over the coming quarters.
Bears Say
Ongoing Cash Burn & LossesPersistent large net losses and negative free cash flow indicate the company remains reliant on internal cash and/or external financing until sustained operating profitability and positive cash generation are realized. Negative equity further constrains balance-sheet flexibility over multiple quarters.
High Gross-to-Net DiscountsVery high gross-to-net deductions structurally compress net sales and make revenue sensitive to payer mix and channel dynamics. This reduces effective pricing power and prolongs the time to convert top-line growth into durable cash flow and earnings, increasing execution risk.
Potential Competitive EntrantA credible new P‑CAB entrant could erode first‑mover advantages, share and pricing. Given VOQUEZNA’s reliance on sustained prescription adoption, competition could slow new starts, increase promotional spend, or necessitate label expansion (e.g., EoE) to defend long‑term franchise value.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals, Inc.’s price range in the past 12 months?
Phathom Pharmaceuticals, Inc. lowest stock price was $7.61 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals, Inc.’s market cap?
Phathom Pharmaceuticals, Inc.’s market cap is $849.40M.
When is Phathom Pharmaceuticals, Inc.’s upcoming earnings report date?
Phathom Pharmaceuticals, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Phathom Pharmaceuticals, Inc.’s earnings last quarter?
Phathom Pharmaceuticals, Inc. released its earnings results on Apr 30, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.08.
Is Phathom Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Phathom Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Phathom Pharmaceuticals, Inc. pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
What is Phathom Pharmaceuticals, Inc.’s EPS estimate?
Phathom Pharmaceuticals, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Phathom Pharmaceuticals, Inc. have?
Phathom Pharmaceuticals, Inc. has 79,755,950 shares outstanding.
What happened to Phathom Pharmaceuticals, Inc.’s price movement after its last earnings report?
Phathom Pharmaceuticals, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -4.924%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.25 (83.85% Upside)
$24.25 (83.85% Upside)
Blogger Sentiment
Neutral
PHAT Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 425.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.71%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
PHAT Stock 12 Month Forecast
Average Price Target
$24.25
▲(83.85% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
9.02% Insiders
13.25% Mutual Funds
2.39% Other Institutional Investors
66.48% Public Companies and
Individual Investors